Robeco Institutional Asset Management B.V. Sells 6,622 Shares of DaVita Inc. (NYSE:DVA)

Robeco Institutional Asset Management B.V. trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 46.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,653 shares of the company's stock after selling 6,622 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in DaVita were worth $1,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DVA. Sanctuary Advisors LLC bought a new stake in DaVita during the 4th quarter valued at about $180,000. Smartleaf Asset Management LLC increased its stake in DaVita by 16.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 712 shares of the company's stock valued at $107,000 after purchasing an additional 101 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of DaVita by 28.6% in the fourth quarter. Jones Financial Companies Lllp now owns 517 shares of the company's stock worth $77,000 after acquiring an additional 115 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of DaVita in the fourth quarter worth approximately $41,000. Finally, Meridian Wealth Management LLC grew its stake in shares of DaVita by 4.9% in the fourth quarter. Meridian Wealth Management LLC now owns 8,747 shares of the company's stock worth $1,308,000 after acquiring an additional 406 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DVA shares. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Truist Financial reduced their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, DaVita currently has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Stock Performance

NYSE DVA remained flat at $142.56 during trading hours on Friday. 600,082 shares of the company traded hands, compared to its average volume of 809,098. The stock has a 50 day simple moving average of $140.06 and a two-hundred day simple moving average of $149.25. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The firm has a market capitalization of $10.76 billion, a price-to-earnings ratio of 14.13, a P/E/G ratio of 0.98 and a beta of 1.11. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.26 earnings per share. On average, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.